Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 201 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference formulation Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.

NCT01551797
View directory record Official record
Conditions
Pain
Interventions
Paracetamol 500 mg, Paracetamol 1000 mg, Paracetamol 750 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

NCT03112148
View directory record Official record
Conditions
Healthy
Interventions
10 mg dose MR formulations,10 mg dose of tofacitinib IR solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

NCT04881747
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

NCT04211545
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Rabeprazole, CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Azithromycin 600 Mg Tablets, Fed

NCT00834132
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 20, 2026, 12:59 AM EDT
Completed No phase listed Observational

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

NCT04848584
View directory record Official record
Conditions
COVID-19
Interventions
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MK-0616
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Results available

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

NCT02206607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
High Point, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

NCT02086227
View directory record Official record
Conditions
Hypoglycemia
Interventions
Glucagon for Injection (Fresenius Kabi USA), Glucagon for Injection (Bedford Laboratories)
Drug
Lead sponsor
Fresenius Kabi USA, LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

NCT04310527
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants

NCT07130097
View directory record Official record
Conditions
Healthy Participant
Interventions
PF-07220060
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Of Pediatric Appropriate Formulation

NCT00758004
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin pediatric appropriate formulation
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

NCT02049528
View directory record Official record
Conditions
Clinical Pharmacology, Healthy Male Volunteer Study
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 20, 2026, 12:59 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283

NCT07712393
View directory record Official record
Conditions
Asthma
Interventions
GSK5784283
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 12:59 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)

NCT07776665
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)

NCT07481708
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

NCT00853268
View directory record Official record
Conditions
Healthy
Interventions
Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 20, 2026, 12:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

NCT01142063
View directory record Official record
Conditions
Healthy
Interventions
Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

NCT06003465
View directory record Official record
Conditions
Healthy
Interventions
LY3437943, Test, Reference
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

NCT05677867
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Formulation Study of Vabicaserin

NCT00928551
View directory record Official record
Conditions
Healthy Subjects
Interventions
vabicaserin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

NCT02944435
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CB-839 Capsules, CB-839 Tablets
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

NCT01775904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 20, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants

NCT01897389
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 20, 2026, 12:59 AM EDT